Ally Bridge, a Hong Kong VC, Invests in German Biotech

Ally Bridge Group, a Hong Kong-US venture capital firm, participated in the $8.3 million funding of Pieris AG, a Munich preclinical-stage biotech. Pieris develops molecules based on Anticalins, which are artificial proteins based on human lipocalins. It was the first investment Ally Bridge has made in Germany and the fifth round for Pieris. Ally Bridge, a company focused on innovative life science technologies, has made investments in the US, China and Europe. More details.... Share this with colleagues: // //